



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 24, 2014

Via E-mail

Mr. Ben Chang  
Chief Financial Officer  
Rich Pharmaceuticals, Inc.  
9595 Wilshire Blvd., Suite 900  
Beverly Hills, California 90212

**RE: Rich Pharmaceuticals, Inc.**  
**Form 10-K for the Year Ended March 31, 2013**  
**Filed July 1, 2013**  
**File No. 0-54767**

Dear Mr. Chang:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Melissa N. Rocha

Melissa N. Rocha  
Senior Assistant Chief Accountant